header
Image from OpenLibrary

Assessment of safety and efficacy of biological treatment in treatment of juvenile Idiopathic arthritis / Mennat Allah Alaa Eldin Yousef ;Supervised Heba Taher Othman , Rasha Abdelraouf , Walaa Aboelqasem

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Mennat Allah Alaa Eldin Yousef , 2016Description: 119 P. : charts , facsimiles ; 25cmOther title:
  • {uFE97}{uFED8}{uFBFE}{uFBFE}م {uئإؤآ}{uئإؤ٤}{uئإ٨إ}ءة و {uئإآ٣}{uئإئأ}{uئإإ٣}{uئإ٩٤} ا{uئإؤئ}{uئإأأ}{uئإئأ}ج ا{uئإؤئ}{uئإ٩١}{uئآئإ}و{uئإؤئ}و{uئإ٩ئ}{uئإئ٠} {uئإؤ٣}{uئإئ٠} {uئإأآ}{uئإئأ}ج {uئإإ٣}رض ا{uئإؤئ}{uئإ٩٧}{uئآءؤ}{uئإ٨إ}ب ا{uئإؤئ}{uئإإ٣}{uئإؤ٤}{uئإ٨إ}{uئإآآ}ل {uئإإ٣}{uئإ٩ئ}{uئآءؤ}ول ا{uئإؤئ}{uئإآ٣}{uئإ٩١}ب [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics Summary: Background: Juvenile idiopathic arthritis (JIA) is a chronic, autoimmune, inflammatory joint disease. It is the most common rheumatic disease in children and adolescents. Treatment of patients with rheumatoid arthritis (RA) has been advanced considerably over the last two decades through earlier treatment with methotrexate (MTX), low dose glucocorticoids, other disease-modifying antirheumatic drugs (DMARDs), and new biologic agents, targeted to low disease activity or remission. Aim: To study the safety and efficacy of biological DMARDs in patients diagnosed as JIA. Setting and Design: sex months prospective study at a pediatric hospital of Cairo university. Results: There was statistically significant improvement in DAS28-ESR after 6 months of biological treatment, but improvement in DAS28-ESR after 3 months of treatment more than DAS28-ESR after 6 months. Conclusion: our findings indicate that biological DMARDs gave better response than other synthetic DMARDs in treatment of juvenile idiopathic arthritis. The onset of start of biological treatment determines the prognosis. But because of our limited finances, the biological treatment was started late in our patients who gave better response after 3months of treatment than fter 6 months of treatment
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.M.Sc.2016.Me.A (Browse shelf(Opens below)) Not for loan 01010110069808000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.M.Sc.2016.Me.A (Browse shelf(Opens below)) 69808.CD Not for loan 01020110069808000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics

Background: Juvenile idiopathic arthritis (JIA) is a chronic, autoimmune, inflammatory joint disease. It is the most common rheumatic disease in children and adolescents. Treatment of patients with rheumatoid arthritis (RA) has been advanced considerably over the last two decades through earlier treatment with methotrexate (MTX), low dose glucocorticoids, other disease-modifying antirheumatic drugs (DMARDs), and new biologic agents, targeted to low disease activity or remission. Aim: To study the safety and efficacy of biological DMARDs in patients diagnosed as JIA. Setting and Design: sex months prospective study at a pediatric hospital of Cairo university. Results: There was statistically significant improvement in DAS28-ESR after 6 months of biological treatment, but improvement in DAS28-ESR after 3 months of treatment more than DAS28-ESR after 6 months. Conclusion: our findings indicate that biological DMARDs gave better response than other synthetic DMARDs in treatment of juvenile idiopathic arthritis. The onset of start of biological treatment determines the prognosis. But because of our limited finances, the biological treatment was started late in our patients who gave better response after 3months of treatment than fter 6 months of treatment

Issued also as CD

There are no comments on this title.

to post a comment.